Static Chart Neurocrine Biosciences, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
139 ^USD	-2.91%		-2.80%	+5.51%

May. 08	Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	CI
May. 07	Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024	CI

Duration

Period